BLFE
Biolife Sciences Inc
Price:  
0.00 
USD
Volume:  
163,780.00
United States | Health Care Equipment & Supplies
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

BLFE WACC - Weighted Average Cost of Capital

The WACC of Biolife Sciences Inc (BLFE) is 3.8%.

The Cost of Equity of Biolife Sciences Inc (BLFE) is 30.85%.
The Cost of Debt of Biolife Sciences Inc (BLFE) is 5.00%.

Range Selected
Cost of equity 3.20% - 58.50% 30.85%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 5.00% - 5.00% 5.00%
WACC 3.7% - 3.9% 3.8%
WACC

BLFE WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta -0.68 9.14
Additional risk adjustments 2.5% 3.0%
Cost of equity 3.20% 58.50%
Tax rate 26.20% 27.00%
Debt/Equity ratio 183.62 183.62
Cost of debt 5.00% 5.00%
After-tax WACC 3.7% 3.9%
Selected WACC 3.8%

BLFE's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for BLFE:

cost_of_equity (30.85%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (-0.68) + risk_adjustments (2.75%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.